Hemostasis Today

June, 2026
June 2026
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
2930  
Heghine Khachatryan: Pregnancy, Thrombosis, and Aspirin – Who Really Needs Prophylaxis?
Jun 13, 2026, 14:36

Heghine Khachatryan: Pregnancy, Thrombosis, and Aspirin – Who Really Needs Prophylaxis?

Heghine Khachatryan, Editor-in-Chief of Hemostasis Today, Head of Hemophilia and Thrombosis Center at Yeolyan Hematology and Oncology Center, shared Thrombosis Haemostasis‘s post on LinkedIn, adding:

“Pregnancy, Thrombosis, and Aspirin: Who Really Needs Prophylaxis?

The use of low-dose aspirin and anticoagulant thromboprophylaxis during pregnancy remains one of the most debated areas of obstetric hemostasis.

Clinical decisions should be based on a comprehensive assessment of maternal thrombotic risk, previous pregnancy outcomes, the presence of antiphospholipid syndrome, inherited thrombophilia, and other acquired risk factors.

Not every thrombophilia requires treatment, and not every pregnancy loss warrants anticoagulation.

Equally important, aspirin and low-molecular-weight heparin serve different purposes and should be prescribed according to clear clinical indications.

As our understanding of pregnancy-associated thrombosis continues to evolve, individualized, evidence-based care remains essential for achieving the best maternal and fetal outcomes.”

Thrombosis Haemostasis shared a post on LinkedIn about a recent article by Elvira Grandone et al., published in Thrombosis Haemostasis:

TH: Why did you (and your colleagues) write this paper? What was its main purpose?

Elvira Grandone , Maurizo Margaglione and Greg Piazza: We undertook this project to identify predictors of antithrombotic drug prescription during pregnancy in a general obstetric population. The motivation arose from our real-world observation that an increasing number of pregnant women are being routinely prescribed these medications, often without a well-defined evidence base. Our aim was to clarify which clinical factors actually drive prescribing practices.

What are the main conclusions?

E.G, M.G, G.P : The study shows that antithrombotic therapy is frequently prescribed during pregnancy. Among the 1,898 women with available data, 157 (8.3%) received low-dose aspirin (100 mg/day), and 746 (39.3%) received low-molecular-weight heparin (LMWH)—mainly at prophylactic doses—of whom only 49 (2.6%) were treated during pregnancy, with the remainder receiving LMWH postpartum. Antithrombotic use was largely driven by maternal characteristics such as assisted conception, prior preterm birth, pregnancy loss, and cesarean delivery, which were the strongest predictors of prescription. Postpartum LMWH use was primarily associated with cesarean delivery.

What are the paper’s implications?- to the public?-to medical professionals?

E.G, M.G, G.P : To  the public; Women who are pregnant or planning pregnancy should be better informed about the appropriate indications for antithrombotic drugs, so they can understand when these treatments may offer real benefit. To medical professionals; The study emphasizes the need for cautious, evidence-based use of LMWH and aspirin during pregnancy, given the uncertain benefits and the lack of clear association with adverse maternal or fetal outcomes.”

Title: Identifying Thromboprophylaxis and Aspirin Use in Pregnancy: Predictors and Maternal Outcomes – the Italian MoMs Study

Authors: Elvira Grandone, Mario Mastroianno, Felice Sorrentino, Gabriella Cicerone, Donatella Colaizzo, Leonardo Latino, Lorenzo Lo Muzio, Stefano Bettocchi, Lucia Mirabella, Angelo Ostuni, Antonio de Laurenzo, Francesca Gorgoglione, Tiziana Palladino, Pasquale Vaira, Antonella Vimercati, Ettore Cicinelli, Behnood Bikdeli, Eleni Kaldoudi, Luigi Nappi, Gregory Piazza, Maurizio Margaglione

Heghine Khachatryan: Pregnancy, Thrombosis, and Aspirin - Who Really Needs Prophylaxis?

Stay updated on all scientific advances with Hemostasis Today.